6660 — AIM Vaccine Share News
0.000.00%
Last trade - 00:00- HK$1.93bn
- HK$3.99bn
- CNY1.17bn
China's AIM Vaccine up after co says operations, finances normal
Brief: AIM Vaccine Says Phase III Clinical Trial Of Serum-Free Rabies Vaccine Got Satisfactory Results
Brief: AIM Vaccine Co Announces Approval For Issuance Of Unlisted RMB Denominated Ordinary Shares From CSRC
Brief: Aim Vaccine Says HY Revenue RMB540.5 Million, Down 8.6%
Brief: AIM Vaccine Initiates Randomized, Blinded And Comparable Vaccine-Controlled Phase III Trial
Brief: AIM Vaccine Says Bivalent Mrna Vaccine Against Covid-19 Variants Obtained Clinical Trial Approvals
Brief: AIM Vaccine Says Clinical Trial Application For Group's Human Rabies MRNA Vaccine Accepted
Brief: Aim Vaccine Says FY Revenue RMB1.26 Billion
HK-listed AIM Vaccine drops most in 5 months after previous rally
Brief: Aim Vaccine Co Says Inclusion As A Constituent Of Hang Seng Composite Index
Brief: Aim Vaccine Says Proposes To Issue Not More Than 242.2 Million Unlisted RMB Denominated Ordinary Shares
Brief: AIM Vaccine Sees Unaudited Consolidated FY Net Loss RMB203.0 Mln To RMB270.0 Mln
Brief: AIM Vaccine Says MRNA COVID-19 Vaccine Candidates Got Clinical Trial Approvals In Pakistan
Brief: AIM Vaccine Says Unit Got Clinical Trial Approval For EV71-CA16 Bivalent HFMD Vaccine Candidate
Brief: Aim Vaccine Says Freeze-Dried Human Rabies Vaccine Candidate Obtained Clinical Trial Approval
China lithium battery maker CALB slips in HK debut, AIM Vaccine sinks